Claims
- 1. A method for treating an autoimmune disease in a mammalian host, the method comprising:
introducing into said mammalian host a DNA expression cassette comprising: a sequence encoding at least a portion of an autoantigen associated with a pro-inflammatory, Th1-type T cell response, under the regulatory control of a promoter that is active in said mammalian host, under conditions wherein said expression cassette is incorporated into cells of said host and said sequence is expressed; wherein the pro-inflammatory response of T cells that respond to said autoantigen is decreased.
- 2. The method of claim 1, further comprising introducing into said mammalian host a DNA expression cassette comprising a sequence encoding a Th2 cytokine under the regulatory control of a promoter that is active in said mammalian host, under conditions wherein said expression cassette is incorporated into cells of said host and said sequence is expressed.
- 3. The method of claim 2, wherein said Th2 cytokine is IL4.
- 4. The method of claim 3, wherein said IL4 is human IL4.
- 5. The method of claim 2, wherein said sequence encoding said Th2 cytokine and said sequence encoding at least a portion of an autoantigen are present on a single DNA construct.
- 6. The method of claim 2, wherein said sequence encoding said Th2 cytokine and said sequence encoding at least a portion of an autoantigen are present on separate DNA constructs.
- 7. The method of claim 2, wherein said expression construct encoding said Th2 cytokine and said expression construct encoding at least a portion of an autoantigen are co-formulated.
- 8. The method of claim 2, wherein said expression construct encoding said Th2 cytokine and said expression construct encoding at least a portion of an autoantigen are independently formulated.
- 9. The method of claim 1, wherein said autoantigen is a myelin protein.
- 10. The method of claim 9, wherein said myelin protein is proteolipid protein.
- 11. The method of claim 9, wherein said myelin protein is myelin basic protein.
- 12. The method of claim 9, wherein said myelin protein is myelin oligodendrocyte protein.
- 13. The method of claim 9, wherein said myelin protein is myelin associated protein.
- 14. The method of claim 9, wherein said autoimmune disease is a demyelinating disease.
- 15. The method of claim 14, wherein said demyelinating disease is experimental autoimmune encephalitis.
- 16. The method of claim 14, wherein said demyelinating disease is multiple sclerosis.
- 17. The method of claim 1, wherein a plasmid comprises said DNA expression cassette.
- 18. The method of claim 1, wherein said pro-inflammatory response includes expression of IL-2, γ-interferon or IL-15.
- 19. A vaccine comprising:
a DNA construct comprising a sequence encoding at least a portion of an autoantigen associated with a pro-inflammatory, Th1-type T cell response, under the regulatory control of a promoter that is active in a mammalian host; and a sequence encoding a Th2 cytokine under the regulatory control of a promoter that is active in a mammalian host.
- 20. The vaccine of claim 19, wherein said Th2 cytokine is IL4.
- 21. The vaccine of claim 20, wherein said IL4 is human IL4.
- 22. The vaccine of claim 19, wherein said sequence encoding said Th2 cytokine and said sequence encoding at least a portion of an autoantigen are present on a single DNA construct.
- 23. The vaccine of claim 19, wherein said sequence encoding said Th2 cytokine and said sequence encoding at least a portion of an autoantigen are present on separate DNA constructs.
- 24. The vaccine of claim 19, wherein said autoantigen is a myelin protein.
- 25. The vaccine of claim 19, wherein said myelin protein is proteolipid protein.
- 26. The vaccine of claim 19, wherein said myelin protein is myelin basic protein.
- 27. The vaccine of claim 19, wherein said myelin protein is myelin oligodendrocyte protein.
- 28. The vaccine of claim 19, wherein said myelin protein is myelin associated protein.
CROSS-REFERENCES
[0001] This application claims priority to earlier filed International Patent Application Ser. No. PCT/US00/06233, filed Mar. 10, 2000 which application claims priority to U.S. patent application Ser. No. 09/267,590 filed Mar. 12, 1999, both of which applications are incorporated herein by reference in their entirety.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/US00/06233 |
Mar 2000 |
US |
Child |
09947770 |
Sep 2001 |
US |